Lonza Group AG

Lonza Group AG is a Swiss-based global leader in contract development and manufacturing organization (CDMO) services for the pharmaceutical, biotech, and nutrition industries. Founded in 1897, it has evolved from electrochemical manufacturing and power generation into the world's largest pure-play CDMO, with over 30 sites across five continents following the 2021 divestiture of its Specialty Ingredients business for CHF 4.2 billion. The company operates four key segments: Biologics, which dominates revenue at 55.4% and focuses on complex molecules from mammalian cells, microbes, and mRNA; Small Molecules for traditional drugs; Cell & Gene technologies addressing genetic diseases through innovative therapies; and Capsules & Health Ingredients, producing up to 250 billion capsules annually for oral drug delivery. Lonza provides end-to-end solutions from early discovery to commercial-scale production under long-term agreements, leveraging economies of scale, high switching costs, brand reputation, and proprietary know-how. Its role in the financial markets underscores its position as a critical partner in the outsourcing trend transforming biopharma, supporting drug innovation amid industry consolidation.